An efficient algorithm for 3D rectangular box packing

Akyokuş, Selim (Dogus Author) -- Conference full title: 9th International Conference, ETAI 2009, Ohrid, September 26-29, Republic of Macedonia, 2009.Getting highest occupancy rate of capacity of a container is very important for the companies, which deals in shipping or has shipping as a part of their main activities. They have to fit 3D boxes in container with optimum or nearest to optimum placement in order to ship more products with a minimum cost. The problem of fitting the boxes which is different from or the same to each other into a big container in optimum level, is called 3-dimensional packing problem. In this problem, the main objective is to minimize used container volume or wasted container space. This provides the reduction of costs in shipments with the use minimum number of containers

İlaçlarla etkileşim potansiyeline sahip hayvan sağlığında da kullanılan tıbbi bitkiler

Bitkiler, binlerce yıldır hayvanlarda verimin artırılması, hastalıklardan korunma ve tedavi amacıyla kullanılmaktadır. Korunma ve tedavide konvansiyonel ilaçlarla eş zamanlı olarak kullanılan bitkiler, sahip oldukları ikincil bileşikler (alkaloidler, glikozitler, reçineler gibi) nedeniyle ilaçlarla aralarında farmakokinetik (Emilim: taşıyıcılar, kompleks oluşumu, gastrointestinal motilite ve pH; Dağılım: plazma proteinlerine bağlanma; Biyotransformasyon: Faz I ve II tepkimeleri; Atılım: idrar pH'sı ve taşıyıcıların modülasyonu) ve farmakodinamik (antagonizma, sinerjizma ve ilave etki) düzeyde etkileşme potansiyeline sahiplerdir. Bazı etkileşimler ilaç etkinliğinin artması veya potansiyel yan etkilerinin azalması şeklinde ortaya çıksa da bitki-ilaç etkileşimleri çoğunlukla istenmeyen etkiler şeklinde ortaya çıkmaktadır. Bu istenmeyen etkiler farmakokinetik parametrelerde (Ydoruk, Cdoruk, EAA gibi), ilaç etkinliğinde ve toksisite düzeyinde değişiklikler şeklinde meydana gelebilmektedir. Bu derlemede ilaçlarla beraber kullanıldıklarında istenmeyen etkileşim potansiyellerine sahip hayvan sağlığında da kullanılan tıbbi bitkiler ve etkileşim sonucu meydana gelebilecek değişiklikler hakkında bilgi vermek amaçlanmıştır.Plants have been used for thousands of years to increase production, preventing and treatment of diseases in animals. Plants; used simultaneously with conventional drugs in prevention and treatment have the potential to interact with drugs at a pharmacokinetic (Absorption: transporters, complex formation, gastrointestinal motility and pH; Distribution: binding to plasma proteins; Metabolism: Phases I and II reactions; Excretion: urine pH and modulation of transporters) and pharmacodynamic (antagonism, synergism and additive effects) level due to secondary compounds (alkaloids, glycosides, resins, etc.) they have. Although some interactions occur in the form of increased drug efficacy or reduced potential side effects, plant-drug interactions often occur as unwanted effects. These unwanted effects can occur as changes in pharmacokinetic parameters (Cmax, Tmax, and AUC etc.), drug efficacy and toxicity. In this review, it is aimed to give information about medicinal plants, also used in animal health, which have unwanted interaction potential when used with medicines and changes that may occur as a result of the interaction

The frequency of Duchenne muscular dystrophy/Becker muscular dystrophy and Pompe disease in children with isolated transaminase elevation: results from the observational VICTORIA study

IntroductionElevated transaminases and/or creatine phosphokinase can indicate underlying muscle disease. Therefore, this study aims to determine the frequency of Duchenne muscular dystrophy/Becker muscular dystrophy (DMD/BMD) in male children and Pompe disease (PD) in male and female children with isolated hypertransaminasemia.MethodsThis multi-center, prospective study enrolled patients aged 3–216 months with serum alanine transaminase (ALT) and/or aspartate transaminase (AST) levels >2× the upper limit of normal (ULN) for ≥3 months. Patients with a known history of liver or muscle disease or physical examination findings suggestive of liver disease were excluded. Patients were screened for creatinine phosphokinase (CPK) levels, and molecular genetic tests for DMD/BMD in male patients and enzyme analysis for PD in male and female patients with elevated CPK levels were performed. Genetic analyses confirmed PD. Demographic, clinical, and laboratory characteristics of the patients were analyzed.ResultsOverall, 589 patients [66.8% male, mean age of 63.4 months (standard deviation: 60.5)] were included. In total, 251 patients (188 male and 63 female) had CPK levels above the ULN. Of the patients assessed, 47% (85/182) of male patients were diagnosed with DMD/BMD and 1% (3/228) of male and female patients were diagnosed with PD. The median ALT, AST, and CPK levels were statistically significantly higher, and the questioned neurological symptoms and previously unnoticed examination findings were more common in DMD/BMD patients than those without DMD/BMD or PD (p < 0.001).DiscussionQuestioning neurological symptoms, conducting a complete physical examination, and testing for CPK levels in patients with isolated hypertransaminasemia will prevent costly and time-consuming investigations for liver diseases and will lead to the diagnosis of occult neuromuscular diseases. Trial RegistrationClinicaltrials.gov NCT04120168